Trial reportMolecular nutrition & food research2025
Bromelain-Rich Pineapple Extract for the Treatment of Pediatric Patients With Orchiepididymitis: A Randomized Clinical Pilot Study.
Trial report in Molecular nutrition & food research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bromelain-Rich Pineapple Extract for the Treatment of Pediatric Patients With Orchiepididymitis: A Randomized Clinical Pilot Study.Molecular nutrition & food research · 2025Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
A freeze-dried pineapple extract-Brome-Inf, from pineapple by-products of industrial rings production, was enriched in bioactive polypeptides and bromelain by membrane ultrafiltration. Orchiepididymitis (OE), a painful pediatric pathology, was treated with this extract. A pilot, double-blind, randomized study involving 60 pediatric OE patients compared the effects of Brome-Inf to a placebo over a 15-day period, in conjunction with antibiotic treatment. In the present study, the primary objective was to assess the disparity in NSAIDs usage and pain intensity between the Brome-Inf group and the placebo group, utilizing the Wong-Becker, Numerical Rating Scale (NRS), and Visual Analogue Scale (VAS) pain rating scales. Results revealed a significant reduction in VAS and NRS within the Brome-Inf group from Days 1 to 15 compared with placebo. A rapid regression of edema was observed in the active group after 1 week and at the end of the study. We can conclude that oral supplementation with Brome-Inf emerges as a promising co-management option for OE for its action on pain and edema, potentially enhancing the quality of life for affected children. Importantly, due to its well-balanced fruity flavor, the palatability of Brome-Inf was appreciated, ensuring optimal patient compliance and treatment safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.